CD19-STAR-T cells
HXYT-003
Phase 1 mab completed
Quick answer
CD19-STAR-T cells for B Cell Malignancy is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- B Cell Malignancy
- Phase
- Phase 1
- Modality
- mab
- Status
- completed